###### Strengths and limitations of this study

-   We conducted a comprehensive literature search and strictly adhered to the projected methodology. The WHO classification of soft tissue sarcomas was adopted and modified to define a clear terminology for the study selection process.

-   We judged a low risk of bias for the single identified randomised controlled trial, which may serve as the major relevant evidence.

-   Single-arm studies provided some estimation about serious adverse events with transplantation.

-   Some treatments were performed 10--20 years ago. Thus, the results may not be applicable to patients who are treated today.

-   The included studies report various subtypes of non-rhabdomyosarcoma soft tissue sarcomas, and each tumour type may carry an individual risk profile and, therefore, ideally should be evaluated separately.

Introduction {#s1}
============

Soft tissue sarcomas (STS) are a highly heterogeneous group of rare malignant solid tumours of non-epithelial extraskeletal body tissue and are classified on a histogenetic basis.[@R1] The location of the primary tumour can involve any area of the body.[@R2] STS can involve any type of tissue and typically affect muscles, tendons, adipose tissue, blood vessels and joints and commonly present as a painless mass.[@R3] In this review, we investigated non-rhabdomyosarcoma STS (NRSTS) provided that they are categorised as malignant according to the WHO 2002 classification.[@R4] In Western countries about four new cases of NRSTS are estimated per 100 000 population every year, with the Ewing family of tumours excluded from this statistic.[@R5]

Surgery is the standard treatment for localised NRSTS and can be curative if distant dissemination is not present.[@R6] [@R7] Chemotherapy is regarded mainly as a palliative treatment for high-risk patients who are characterised by inoperable, locally advanced and metastatic disease.[@R6] Riedel[@R8] provides an overview of current systemic therapies and discusses possible novel therapeutic agents and treatment strategies. High-dose chemotherapy (HDCT) has been evaluated as an alternative treatment option for high-risk patients. The rationale for HDCT is that escalating doses of HDCT may increase survival by capturing putatively remnant malignant cells.[@R9] The rationale for autologous haematopoietic stem cell transplantation (HSCT) following HDCT is a planned rescue for HDCT-related severe haematological toxicity.[@R9] The primary objective of the present systematic review is to evaluate the effectiveness and adverse events of autologous HSCT following HDCT in patients with advanced or metastatic NRSTS.

Methods {#s2}
=======

This article is based on a Cochrane systematic review published in The Cochrane Library.[@R10] Publication of this work is in agreement with the policy of The Cochrane Collaboration.[@R11] While preparing this systematic review, we endorsed the PRISMA statement, adhered to its principles and conformed to its checklist.[@R12]

Study inclusion criteria {#s2a}
------------------------

We included patients with NRSTS provided that they are categorised as malignant according to the WHO 2013 classification on STS[@R4] as well as malignant haemangiopericytoma and anaplastic sarcoma. We excluded the Ewing family of tumours according to the European Society for Medical Oncology (ESMO) Guidelines Working Group,[@R5] chondrosarcomas, osteosarcomas and rhabdomyosarcomas. While writing the Cochrane Review, we referred to the WHO 2002 classification.[@R13] For the purpose of the present systematic review, we updated the inclusion criteria and re-evaluated the potentially relevant studies and included the following entities: 'Gastrointestinal Stromal Tumours', 'Malignant peripheral nerve sheath tumour', 'Undifferentiated pleomorphic sarcoma not otherwise specified'. Almost all published studies refer to the 2002 classification. Thus, we continued to include the following entities though they were removed and relocated within the 2013 classification: 'malignant fibrous histiocytoma' (MFH), 'undifferentiated sarcoma', 'unclassified sarcoma', and 'haemangiopericytoma'. [Table 1](#BMJOPEN2014005033TB1){ref-type="table"} compares the categories and malignant subtypes of the 2013 versus the 2002 edition of the WHO classification of tumours of soft tissue and indicates which of those are included in the present systematic review. Participants were included regardless of age, severity and clinical stage of disease. Studies were included as long as at least 80% of patients had NRSTS and received the test intervention. The test intervention was autologous HSCT following HDCT containing stem cells from peripheral blood or bone marrow. The comparator was standard-dose chemotherapy (SDCT). The primary outcomes were overall survival and treatment-related mortality (TRM). Secondary outcomes were disease-free survival, progression-free survival, event-free survival, non-haematological toxicity grades 3--4,[@R14] secondary malignant neoplasia and health-related quality of life.

###### 

Inclusion of malignant soft tissue tumours of the WHO classification 2013 vs 2012

  Category                                 Malignant subtypes                                             2013   2002   Inclusion
  ---------------------------------------- -------------------------------------------------------------- ------ ------ -----------
  Adipocytic tumours                                                                                      2013   2002   Included
                                           Dedifferentiated liposarcoma                                   2013   2002   Included
                                           Myxoid liposarcoma                                             2013   2002   Included
                                           Pleomorphic liposarcoma                                        2013   2002   Included
                                           Liposarcoma, not otherwise specified                           2013   2002   Included
                                           Round cell liposarcoma                                         No     2002   Included
                                           Mixed-type liposarcoma                                         No     2002   Included
  Fibrobastic/myofibroblastic tumours                                                                     2013   2002   Included
                                           Adult fibrosarcoma                                             2013   2002   Included
                                           Myxofibrosarcoma                                               2013   2002   Included
                                           Low-grade fibromyxoid sarcoma                                  2013   2002   Included
                                           Sclerosing epitheloid fibrosarcoma                             2013   2002   Included
                                           Malignant haemangiopericytoma                                  No     No     Included
  So-called fibrohistiocytic tumours                                                                      2013   2002   Included
                                           Pleomorphic 'MFH\'/(UPS)                                       No     2002   Included
                                           Giant cell 'MFH\'/UPS with giant cells                         No     2002   Included
                                           Inflammatory 'MFH\'/UPS with prominent inflammation            No     2002   Included
  Smooth muscle tumours                                                                                   2013   2002   Included
                                           Leiomyosarcoma (excluding skin)                                2013   2002   Included
  Pericytic (perivascular) tumours                                                                        2013   2002   No
  Skeletal muscle tumours                                                                                 2013   2002   No
                                           Embryonal rhabdomyosarcoma                                     2013   2002   No
                                           Alveolar rhabdomyosarcoma                                      2013   2002   No
                                           Pleomorhic rhabdomyosarcoma                                    2013   2002   No
                                           Spindle cell/sclerosing rhabdomyosarcoma                       2013   No     No
  Vascular tumours of soft tissue                                                                         2013   2002   Included
                                           Epithelioid haemangioendothelioma                              2013   2002   Included
                                           Angiosarcoma of soft tissue                                    2013   2002   Included
  Chondro-osseous tumours                                                                                 2013   2002   No
                                           Mesenchymal chondrosarcoma                                     2013   2002   No
                                           Extraskeletal osteosarcoma                                     2013   2002   No
  Gastrointestinal stromal tumours                                                                        2013   No     Included
                                           Gastrointestinal stromal tumour, malignant                     2013   No     Included
  Nerve sheath tumours                                                                                    2013   No     Included
                                           Malignant peripheral nerve sheath tumour                       2013   No     Included
                                           Epithelioid malignant peripheral nerve sheath tumour           2013   No     Included
                                           Malignant Triton tumour                                        2013   No     Included
                                           Malignant granular cell tumour                                 2013   No     Included
                                           Ectomesenchymoma                                               2013   No     Included
  Tumours of uncertain differentiation                                                                    2013   2002   Included
                                           Synovial sarcoma NOS                                           2013   2002   Included
                                           Epithelioid sarcoma                                            2013   2002   Included
                                           Alveolar soft-part sarcoma                                     2013   2002   Included
                                           Clear cell sarcoma of soft tissue                              2013   2002   Included
                                           Extraskeletal myxoid chondrosarcoma                            2013   2002   No
                                           Extraskeletal Ewing sarcoma                                    2013   2002   No
                                           Desmoplastic small round cell tumour                           2013   2002   Included
                                           Extrarenal rhabdoid tumour                                     2013   2002   Included
                                           Neoplasms with perivascular epithelioid cell differentiation   2013   2002   Included
                                           Intimal sarcoma                                                2013   2002   Included
                                           Malignant Mesenchymoma                                         No     2002   Included
  Undifferentiated/unclassified sarcomas                                                                  2013   No     Included
                                           Undifferentiated spindle cell sarcoma                          2013   No     Included
                                           UPS                                                            2013   No     Included
                                           Undifferentiated round cell sarcoma                            2013   No     Included
                                           Undifferentiated epithelioid sarcoma                           2013   No     Included
                                           Undifferentiated sarcoma NOS                                   2013   No     Included

MFH, malignant fibrous histiocytoma; NOS, not otherwise specified; UPS, undifferentiated pleomorphic sarcoma.

Search strategy, selection of studies and data extraction {#s2b}
---------------------------------------------------------

We conducted an electronic literature database search in MEDLINE (Ovid), EMBASE (Ovid) and Cochrane Library CENTRAL (Wiley) including articles published from inception to an update search on 12 June 2014. The corresponding search strategies have been published in the corresponding Cochrane Review.[@R10] We retrieved all titles and abstracts by electronic searching and downloaded them to the reference management database EndNote V.X3.[@R15] We considered studies written in languages other than English. We searched the online registries[@R16] [@R17] on 12 June 2014 for additional completed or ongoing studies using the search strategy \"sarcoma AND chemotherapy AND transplantation\". We searched all retrieved abstracts of annual meetings contained in EMBASE (Ovid). We contacted authors to replenish missing information. All data assessments were performed independently by two independent review authors. We resolved differences by discussion or by appeal to a third review author. We judged whether the autologous HSCT following HDCT could be regarded as a consolidation or a salvage therapy. A consolidation therapy is a treatment that is given after cancer has disappeared following the initial therapy and a salvage therapy is a treatment that is given after the cancer has not responded to other treatments.[@R18] We considered a consolidation therapy if the status at transplantation was either a complete or a partial response to the preceding therapy and we considered a salvage therapy if the status was less favourable and in case a relapse was described.

Assessment of risk of bias in included studies {#s2c}
----------------------------------------------

We have used four criteria from The Cochrane Collaboration's tool for assessing risk of bias in randomised controlled trials (RCTs)[@R19]: random sequence generation, allocation concealment, blinding of outcome assessment and selective reporting such as not reporting prespecified outcomes. We extended the Cochrane tool for assessing risk of bias by five criteria that consider non-randomised studies: prospective design, comparable baseline characteristics, assignment of patients to treatment groups, concurrent control, and loss to follow-up. We applied The Cochrane Collaboration\'s criteria for judging risk of bias.[@R20]

Data synthesis {#s2d}
--------------

We synthesised aggregate data as narrative because data were too scarce to be pooled. Differently from the Cochrane Review, we did not pool time-to-event data on overall survival from studies with individual data. With respect to survival data, we accepted time of diagnosis and beginning of treatment as starting points. We evaluated all 62 studies to search for reports on TRM and tabulated the identified patient data. We evaluated the seven studies reporting aggregate data to search for reports on grade 3--4 non-haematological toxicity in the autologous HSCT following the HDCT arm and tabulated the identified event data.

Results {#s3}
=======

Search results {#s3a}
--------------

[Figure 1](#BMJOPEN2014005033F1){ref-type="fig"} shows the literature search and study flow. We retrieved 1035 records and evaluated 260 full text papers in detail. We included 62 studies with 294 transplanted patients, 1 RCT with 38 transplanted and 45 non-transplanted patients,[@R21] 6 single-arm studies reporting aggregate case series data,[@R22] and 55 single-arm studies with individual data. In online registries, we identified 6 studies with a still pending completion and we did not find additional studies in the update search.

![Literature search and study flow.](bmjopen2014005033f01){#BMJOPEN2014005033F1}

Baseline data {#s3b}
-------------

We provide an overview of the main characteristics of studies and treatment ([table 2](#BMJOPEN2014005033TB2){ref-type="table"}), of the patients ([table 3](#BMJOPEN2014005033TB3){ref-type="table"}) and of the frequency of the identified subtypes ([table 4](#BMJOPEN2014005033TB4){ref-type="table"}). The one RCT was an open, multicenter and randomised phase III study with two parallel treatment groups.[@R21] Patients were eligible for randomisation if they had responded to chemotherapy or, for stable disease, if a complete surgical resection of all disease sites could be carried out. The intention-to-treat principle was modified to exclude patients found to be ineligible at a histological review after randomisation. Three of the six single-arm studies reporting aggregate case series data collected the data prospectively[@R22] and three retrospectively.[@R25] Data from the remaining 55 single-arm studies were considered for the description of TRM only.

###### 

Characteristics of studies and therapy

  Study                              Number of centers (country)   Enrolment; years   Prospective design   Autologous HSCT following HDCT                    
  ---------------------------------- ----------------------------- ------------------ -------------------- -------------------------------- ---------------- -----------------
  Aggregate comparative data                                                                                                                                 
   Bui-Nguyen *et al*[@R21]          16 (France)                   2000--2008         Yes                  Ca-Et-If                         38 vs 0 vs 0     38 vs 0 vs 0
  Aggregate case series data                                                                                                                                 
   Bertuzzi *et al*[@R22]            1 (Italy)                     1997--2002         Yes                  Me-Mi-Th                         10 vs 0 vs 0     10 vs 0 vs 0
   Bisogno *et al*[@R23]             \>1 (Italy)                   1999--2008         Yes                  Cy-Me-Th                         14 vs 0 vs 0     14 vs 0 vs 0
   Blay *et al*[@R24]                1 (France)                    1988--1994         Yes                  Ci-Et-If                         0 vs 0 vs 24     0 vs 0 vs 24
   Bokemeyer *et al*[@R25]           3 (Germany)                   NR                 No                   Do-If                            16 vs 0 vs 0     16 vs 0 vs 0
   Cook *et al*[@R26]                29 (USA)                      1999--2007         No                   Ca-Cy-Et-Me-Th                   0 vs 0 vs 36     33 vs 2 vs 1
   Philippe-Chomette *et al*[@R27]   \>1 (France)                  1995--2006         No                   Various                          14 vs 0 vs 0     0 vs 0 vs 14
  Individual cases data                                                                                                                                      
   55 studies (142 patients)         Various                       Various            No                   Various                          69 vs 61 vs 12   102 vs 21 vs 19

BMT, bone marrow transplant; Ca, carboplatin; Ci, cisplatin; Cy, cyclophosphamide; Do, Doxorubicin; Et, etoposide=Vepesid=VP 16; HDCT, high-dose chemotherapy; HSCT, autologous haematopoietic stem cell transplantation; If, ifosfamide; Me, melphalan; Mi, mitoxantrone; N, number; NR, information not reported in the article; PBSCT, peripheral blood stem cell transplant; Th, thiotepa.

###### 

Characteristics of patients

  Study                              Patients analysed; N   FU   Subtypes        Age; median years (range)   Gender; % males                         
  ---------------------------------- ---------------------- ---- --------------- --------------------------- ----------------- --------------- ----- ----
  Aggregate comparative data                                                                                                                         
   Bui-Nguyen *et al*[@R21]          38                     45   55 (NR)         Various                     46 (19 to 65)     43 (18 to 65)   58    50
  Aggregate case series data                                                                                                                         
   Bertuzzi *et al*[@R22]            10                     NA   35 (14 to 60)   DSRCT                       29 (NR)           NA              100   NA
   Bisogno *et al*[@R23]             14                     NA   27 (NR)         DSRCT                       10 (2 to 17)      NA              93    NA
   Blay *et al*[@R24]                24                     NA   NR              Various                     NR                NA              NR    NA
   Bokemeyer *et al*[@R25]           16                     NA   NR              Various                     45 (25 to 57)     NA              NR    NA
   Cook *et al*[@R26]                36                     NA   44 (4 to 89)    DSRCT                       19 (8 to 46)      NA              80    NA
   Philippe-Chomette *et al*[@R27]   14                     NA   23 (9 to 51)    DSRCT                       NR (4 to 29)      NA              86    NA
  Individual cases data                                                                                                                              
   55 studies                        142                    NA   Various         Various                     25 (1 to 65)      NA              NR    NA

DSRCT, desmoplastic small-round cell tumour; FU, follow-up of the analysed patients in median months (range); HSCT, autologous haematopoietic stem cell transplantation following high-dose chemotherapy; N, number; NA, not applicable; NR, information not reported in the article; SDCT, standard-dose chemotherapy.

###### 

Frequency of subtypes

  Subtype                                      All   Aggregate   Individual
  -------------------------------------------- ----- ----------- ------------
  Anaplastic sarcoma                           5     0           5
  Angiosarcoma                                 10    4           6
  Clear cell sarcoma                           2     1           1
  Desmoplastic small round cell tumour         109   74          35
  Epitheloid sarcoma                           2     0           2
  Fibrosarcoma                                 6     1           5
  Fibromyosarcoma                              1     0           1
  Leiomyosarcoma                               29    14          15
  Liposarcoma                                  15    8           7
  Mesenchymal sarcoma                          2     2           0
  Malignant fibrous histiocytoma               31    13          18
  Malignant haemamgiopericytoma                8     5           3
  Malignant peripheral nerve sheath tumour     4     0           4
  Rhabdoid tumour, extrarenal, extracerebral   2     0           2
  Spindle cell sarcoma                         1     0           1
  Synovial sarcoma                             32    9           23
  Unclassified sarcoma                         17    12          5
  Undetermined sarcoma                         13    4           9
  Not NRSTS                                    5     5           0
  Total number                                 294   152         142

NRSTS, non-rhabdomyosarcoma soft tissue sarcomas.

The 62 studies were set in 13 different countries in four different continents. Most of the transplanted patients were studied in France, USA and Germany. We assume that most patients in the studies reporting aggregate case series data received autologous HSCT following HDCT as a consolidation therapy, whereas a considerable number of the individual case data were associated with autologous HSCT following HDCT as a rescue therapy. The majority of all studies used peripheral blood stem cell transplants. Median age varied roughly between 19 and 46 years and there was a male preponderance. Patients had 19 different relevant histological diagnoses. Most patients had desmoplastic small round-cell tumour (N=109 of 294) followed by the new category of undifferentiated pleomorphic sarcomas (N=61), which is composed of MFH (N=31), unclassified sarcoma (N=17) and undetermined sarcoma (N=13).

Primary outcome {#s3c}
---------------

Overall survival was not statistically significantly different in the RCT by Bui-Nguyen *et al*[@R21] between autologous HSCT following HDCT versus SDCT regarding the HR of 1.26 (95% CI 0.70 to 2.29; p=0.44; [table 5](#BMJOPEN2014005033TB5){ref-type="table"}). In this RCT, the point estimates at 3 years were 32.7% vs 49.4% based on 8 vs 17 remaining patients at risk. The patients at risk at baseline were 38 vs 45 patients. With respect to the studies reporting aggregate case series data, overall survival for transplanted patients ranged roughly from 20% to 51% at 2 years and from 32% to 40% at 3 years ([table 5](#BMJOPEN2014005033TB5){ref-type="table"}). In 10 studies, TRM was associated with 15 of 137 evaluated patients ([table 6](#BMJOPEN2014005033TB6){ref-type="table"}). Assuming no other TRM in the remaining 157 patients, a risk o procedure-related death might be estimated as 5.1% (15 of 294).

###### 

Overall survival in studies reporting aggregate data

  Study                              Overall survival (95% CI), point estimates   Statistics                 
  ---------------------------------- -------------------------------------------- ------------------ ------- --------------------------------
  Aggregate comparative data                                                                                 
   Bui-Nguyen *et al*[@R21]                                                       32.7%              49.4%   HR 1.26 (0.70 to 2.29), p=0.44
  Aggregate case series data                                                                                 
   Bertuzzi *et al*[@R22]            20%                                          NR                 NA      
   Bisogno *et al*[@R23]             48%                                          38.9%              NA      
   Blay *et al*[@R24]                NR                                           NR                 NÁ      
   Bokemeyer *et al*[@R25]           Median 13 months, range 3--19                                   NA      
   Cook *et al*[@R26]                NR                                           40% (24% to 58%)   NA      
   Philippe-Chomette *et al*[@R27]   51.4% (23.2% to 79.6%)                       NR                 NA      

Some estimates were deduced from Kaplan-Meier plots.

HSCT, autologous haematopoietic stem cell transplantation following high-dose chemotherapy; NA, not applicable; NR, not reported, SDCT, standard-dose chemotherapy.

###### 

Treatment-related mortality in the HSCT arm of all included studies

  Study                              N affected/ N evaluated patients   Specification
  ---------------------------------- ---------------------------------- -----------------------------------------------------------------
  Treatment-related mortality                                           
   Bui-Nguyen *et al*[@R21]          1/38                               Treatment-related leukaemia death 2 years after HSCT
   Cook *et al*[@R26]                2/36                               NR
   Doros *et al*[@R41]               1/1                                NR
   Engelhardt *et al*[@R42]          3/24                               Sepsis (N=2); pneumonia related to lung metastases (N=1)
   Kasper *et al*[@R43]              1/14                               Cardiac arrest of unknown cause
   Matsuzaki *et al*[@R44]           1/1                                Multiple organ failure
   Navid *et al*[@R45]               1/2                                Liver as well as kidney failure
   Philippe-Chomette *et al*[@R27]   1/14                               Died of treatment toxicity 12 months after HSCT
   Saab *et al*[@R46]                2/4                                Acute myocardial infarction (N=1); veno-occlusive disease (N=1)
   Slease *et al*[@R47]              2/3                                Progressive encephalopathy (N=1); sepsis (N=1)
   Total                             15/137                             

HSCT, autologous haematopoietic stem cell transplantation following high-dose chemotherapy; N, number; NR, not reported.

Secondary outcomes {#s3d}
------------------

Progression-free survival was also not statistically significantly different in the RCT by Bui-Nguyen *et al*[@R21] between autologous HSCT following HDCT versus SDCT regarding the HR of 1.34 (95% CI 0.81 to 2.20; p=0.25). In this RCT, the point estimates at 3 years were 9.3% vs 21.6% based on 3 vs 12 remaining patients at risk. The RCT did not report results on disease-free survival and event-free survival. An overview of the number of events of non-haematological toxicity grade 3--4 is provided in [table 7](#BMJOPEN2014005033TB7){ref-type="table"}. In the RCT, 11 events were observed in 38 transplanted patients and 1 event (asthenia) was reported regarding the SDCT arm. In 3 of the studies reporting aggregate case series data, 25 events were observed in 54 transplanted patients in the HSCT arm. The other 3 studies did not report toxicity data. We identified one secondary neoplasia in a single case report. Health-related quality of life scales were not addressed in the included studies.

###### 

Grade 3--4 NCI-CTCAE non-haematological toxicity in the HSCT arm of studies reporting aggregate case series data

  Study                              N events/ N evaluated patients   Specification
  ---------------------------------- -------------------------------- ----------------------------------------------------------------------------------------------------------
  Aggregate comparative data                                          
   Bui-Nguyen *et al*[@R21]          11/38                            Digestive (N=8); infection (N=2); pain (N=1)
  Aggregate case series data                                          
   Bertuzzi *et al*[@R22]            NR                               NA
   Bisogno *et al*[@R23]             1/14                             Mucositis grade 4
   Blay *et al*[@R24]                16/24                            Neurological grade 4 (N=1); lung grade 3/4 (N=2); renal grade 3/4 (N=5); nausea/vomiting grade 3/4 (N=8)
   Bokemeyer *et al*[@R25]           8/16                             No grade 4; neurological (N=1); renal (N=2); infection (N=1); mucositis (N=2); nausea/emesis (N=2)
   Cook *et al*[@R26]                NR                               NA
   Philippe-Chomette *et al*[@R27]   NR                               NA

HSCT, autologous haematopoietic stem cell transplantation following high-dose chemotherapy; N, number; NA, not applicable; NR, not reported; NCI-CTCAE, National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade III--IV.[@R14]

Data quality {#s3e}
------------

Clinical heterogeneity was substantial because tumour subdiagnosis varied considerably between patients. Furthermore, tumour stage and metastasis were not reported for all participants. The RCT by Bui-Nguyen *et al*[@R21] stands out as it is the only study reporting comparative data. We judged a low risk of bias for this trial for random sequence generation and selective reporting. However, the trial does have some drawbacks. We judged an unclear risk for allocation concealment because masking of allocation was not described in full detail. We judged a high risk of bias for blinding of outcome assessment because it was not reported for any outcome. The other 61 of 62 studies are single-arm studies and are therefore not qualified for assessing a treatment effect.

Discussion {#s4}
==========

Outcomes {#s4a}
--------

We identified one RCT comparing autologous HSCT following HDCT versus SDCT.[@R21] The authors reported a difference in overall survival and progression-free survival after the treatment in favour of SDCT but the difference was not statistically significant, respectively. Therefore, there is evidence that patients may not have a better survival after autologous HSCT following HDCT versus SDCT. If at all, this intervention should only be offered after careful consideration and preferably only within a randomised controlled clinical trial. We estimated a TRM of 5.1%, which was somewhat higher than the 2% reported by others.[@R28] Severe toxicity grade 3--4 was sparsely reported. Studies on health-related quality of life were not identified. The frequency of secondary neoplasia in 1 of 294 participants is probably an extreme underestimation of the true frequency due to a relatively short follow-up. The detection of secondary neoplasia depends on a long follow-up and was estimated from 4% to 6.9% by others.[@R29] [@R30]

The WHO 2013 classification {#s4b}
---------------------------

The WHO recently published the 2013 classification on STS.[@R4] The authors inserted the category 'Undifferentiated Pleomorphic Sarcoma Not Otherwise Specified' to lodge those types of STS that are difficult to classify using the current available techniques.[@R31] [@R32] The authors integrated the terms 'MFH', 'Undifferentiated Sarcoma', and 'Unclassified Sarcoma' into this newly created category. MFH was characterised by an apparent lack of specific differentiation[@R33] and it was considered a diagnosis of exclusion.[@R34] MFH was regarded as the most common soft tissue sarcoma of adulthood[@R33] and accounted for up to 25% of patients in clinical trials on soft tissue sarcoma.[@R34] In 1992, Fletcher[@R33] reassessed 159 cases with MFH and found 63% (97 of 159) tumours to be specific sarcomas other than MFH. In 2001, Fletcher *et al*[@R35] confirmed that 84% (84 of 100) tumours of patients with MFH showed sufficient differentiation to assign them to specific subtypes of STS. The techniques to assess cell differentiation have been substantially improved with the effect that the frequency of the tumour within this category has decreased.[@R36] It was supposed that the category of 'Undifferentiated Sarcoma---Otherwise Not Specified' may contain liposarcoma, fibrosarcoma, leiomyosarcoma, rhabdomyosarcoma, other sarcomas, and even carcinomas or lymphomas.[@R36] [@R37] It was estimated that the pathologist might have difficulties in identifying a specific differentiation in 10--15% of tumours previously called MFH.[@R37] The new edition also removed the term 'Haemangiopericytoma'.[@R31] [@R32] 'Gastrointestinal Stromal tumours' and 'Nerve Sheath tumours' were relocated from other classifications and appear for the first time in the soft tissue classifications.[@R31] [@R32] Consequently, the term 'Malignant Peripheral Nerve Sheath Tumour' is newly integrated.

Strengths and limitations {#s4c}
-------------------------

The search strategy had the broad aim of the retrieval of all relevant studies. With respect to historical versions of the Cochrane Review,[@R10] we applied two different search strategies and retrieved the same studies with aggregate data but different studies with individual cases data. These results show the substantial difficulty associated with the aim of searching for all published cases. This enterprise appears almost impossible. We adopted the new WHO 2013 classification of STS and made minor modifications to define a clear terminology for the study selection process. The group of NRSTS consists of many subtypes that are difficult to diagnose and separate even today. A considerable number of tumours cannot be clearly assigned to a specific histological category. Thus, we may have tumours with a specific label that might not be true. Otherwise, we may have tumours without a specific label that might belong to a specific category. We excluded studies if the proportion of non-eligible participants were greater or equal to 20% of the total population to prevent a significant mixture with disease or interventions that are not included in the present review. Authors were contacted to ask for additional data. We judged a low risk of bias for the one identified RCT, which may serve as the major relevant evidence. All other identified studies were single-arm studies that are not helpful in deciding whether autologous HSCT following HDCT for NRSTS is a meaningful treatment option. Therefore, we removed the survival data of studies reporting individual data. Nevertheless, they provided data for estimation about TRM within all included transplanted patients. We also removed data on non-haematological toxicity of studies reporting individual data because the sparse reporting might have caused a display of non-representative information. The description of consolidation and salvage therapy is based on our judgement and might be judged differently by others. These types of therapy were not precisely reported in most studies. Some treatments were performed 10--20 years ago. Thus, the results may not be applicable to patients who are treated today. All studies report various subtypes of NRSTS and each tumour type may carry an individual risk profile and, therefore, ideally should be evaluated separately. With respect to the individual survival data, follow-up started at different time points, that is, at diagnosis or at start of treatment. The delay between diagnosis and starting HDCT can be considerable.

Other findings and opinions {#s4d}
---------------------------

We wish to point out that some authors have warned against the use of autologous HSCT following HDCT, indicating the possibility of repositioning of malignant cells.[@R38] Others have questioned the use of HDCT with reference to the potential existence of refractory cancer stem cells.[@R9] Pedrazzoli *et al*[@R39] stated that the potential benefit of this treatment option has not been investigated sufficiently in comparative studies. Kasper *et al*[@R40] concluded that the use of HDCT for locally advanced or metastatic adult (soft tissue and bone) sarcomas still remains highly investigational and should not be performed outside clinical trials. The identified RCT by Bui-Nguyen *et al*[@R21] provides meaningful comparative data for the first time and its results questions any benefit of the intervention. Finally, we cannot close the chapter as it can be unsecure to rely on a single trial.

Conclusion {#s5}
==========

Overall survival in patients with locally advanced or metastatic NRSTS was not statistically different after autologous HSCT following HDCT compared with SDCT in a single RCT with a total of 83 patients. No other comparative study was available. A considerable number of patients were not evaluated concerning adverse events, and its proportion among the transplanted patients remains unclear. If this treatment is offered it should only be after careful consideration and only within an RCT.
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